Isomorphic Labs, an Alphabet-backed AI drug discovery company, has hired its first U.S.-based chief medical officer and established an office in Cambridge to facilitate clinical advancement of AI-designed candidates. The startup builds on the success of AlphaFold by deploying AI to transform drug development pipelines, emphasizing partnerships and strategic presence in biotech hubs. This move underscores the increasing role of AI in accelerating pharmaceutical innovation and bridging computational models with clinical translation.